Olema Pharmaceuticals Inc... (OLMA)
Olema Pharmaceuticals Inc. (OLMA) Stock Price, Analysis & Data
| Geld | 8.05 |
| Marktkapitalisierung | 942.35 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -204.57 Mio |
| Beta | 2.01 |
| EPS (ttm) | -2.12 |
| KGV (TTM) | n/a |
| Forward-KGV | -4.01 |
| KBV (TTM) | 2.19 |
| KUV (TTM) | n/a |
| Earnings Date | Nov 9, 2026 |
| Brief | 14.06 |
| Volumen | 810,817 |
| Ø Vol. (20D) | 1,424,543 |
| Eröffnung | 10.90 |
| Vortagesschluss | 10.65 |
| Tagesspanne | 10.85 - 11.32 |
| 52-Wk Range | 5.34 - 36.26 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative ...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Olema Pharmaceuticals 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -162.45 Mio, ein Anstieg von 25.47 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 2 Monaten · Simply Wall St.
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation GapOlema Pharmaceuticals (NasdaqGS:OLMA) reported preliminary Phase 1 data for oral KAT6 inhibitor OP-3136, showing anti-tumor activity in multiple advanced solid tumors. The early readout highlighted tu...
